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TGF-f31-induced cell cycle arrest in renal mesangial cells
involves inhibition of cyclin E-cdk 2 activation and
retinoblastoma protein phosphorylation
HARALD 0. SCHOECKLMANN, HARALD D. RUPPRECHT, Ii ZAUNER, and R. BERND STERZEL
Medizinische Klinik IV Universität Erlangen-Nurnberg, Erlangen, Germany
TGF.j31.induced cell cycle arrest in renal mesangial cells involves
inhibition of cydlin E-cdk 2 activation and retinoblastoma protein phos-
phorylation. In glomerular disease, transforming growth factor-/H (TGF-
/31) has been demonstrated to exert anti-mitogenic and anti-inflammatory
as well as fibrogenic effects. To better understand the TGF-131 action on
glomerular cells at the molecular level, we investigated mechanisms of
TGF-/31-induced growth suppression in primary cultures of rat mesangial
cells (MCs). TGF-f31 (5 nglml) markedly inhibited proliferation of MCs
incubated with PDGF, endothelin-1, bFGF, serotonin, or EGF, indicating
that TGF-/31 interferes with post-receptor signals of mitogenesis. TGF-/31
did not affect mitogen-stimulated induction of the immediate early genes,
c-fos, c-fun, and Egr-1 in MCs that occurred transiently at 30 to 120
minutes. Time-course studies revealed that TGF-/31 inhibited DNA
synthesis and MC replication when added up to six to eight hours after
MC stimulation with PDGF. FACS analysis demonstrated that MCs had
reached middle to late G1 phase of cell cycle progression at this timepoint.
PDGF stimulation of MCs induced protein expression of the G phase
cyclin Dl as well as the cyclin-dependent kinases cdk 4 and cdk 2. This was
not significantly altered when MCs were coincubated with both, PDGF
and TGF-/31. However, TGF-/31 prevented PDGF-elicited phosphoryla-
tion of the retinoblastoma tumor suppressor (pRb), a negative cell cycle
regulator. Moreover, TGF-/31 significantly reduced cyclin E-associated
histone Hi kinase activity in the presence of PDGF. These results indicate
that TGF-/31 inhibits mitogen-stimulated MC growth by causing cell cycle
arrest in late G1 phase. While TGF-/31 does not alter the mitogen-induced
expression and abundance of G1 phase cyclin Dl and cdks 4 and 2 in MCs,
it inhibits cyclin E-cdk 2 activity, thus preventing mitogen-elicited phos-
phorylation and inactivation of pRb in G phase and transition to S phase.
Maintenance of normal tissue integrity in the adult organism
requires tight control of cellular growth. In inflammatory re-
sponses to tissue injury, induction of cell proliferation is an
important part of local repair mechanisms. Once the lesion is
overcome, the ensuing healing process requires reversal of hyper-
cellularity in order to restore normal tissue structure and function.
Thus, cellular responses during inflammation include both pro-
mitogenic and anti-mitogenic mechanisms.
Cell hyperplasia in the glomenilar mesangium due to mesangial
cell (MC) proliferation is a prominent histopathological finding in
many types of glomerular inflammatory diseases, including IgA
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nephropathy, membranoproliferative glomerulonephritis, postin-
fectious endocapillary proliferative glomerulonephritis and lupus
nephritis. Increased MC proliferation reflects a common reaction
pattern of the glomerulus in response to a variety of injuries. It
appears to play an early and potentially crucial role in the
pathogenesis of progressive glomerular lesions and glomerular
sclerosis, which may lead to irreversible loss of renal function.
Indeed, in different experimental models of glomerular injury it
has been observed that persistent MC proliferation is associated
with expansion of the mesangial extracellular matrix (ECM) and
glomerular sclerosis [1, 21. Moreover, experimental interventions
inhibiting MC proliferation have been reported to limit mesangial
ECM build-up and to lessen fall of renal function [3, 1. Numer-
ous in vitro studies have identified substances which induce MC
proliferation including, for instance, various peptide growth fac-
tors and nuclear transcription factors mediating the mitogenic
response [5, 6]. The present study addressed the question, which
cellular events are involved in anti-mitogenic effects on MCs. In
particular, we studied molecular mechanisms of TGF-f31-related
growth suppression in cultured MCs.
It has been shown that TGF-f3 is produced by MCs in a
constitutive fashion and can act upon MCs in an autocrine
manner, including the induction of its own synthesis [7]. Of the
three isoforms of TGF-J3 that have been identified in mammalian
species, most data have been generated in studies of the 131
subtype, a 25 kDa homodimer. A recent histochemical study
demonstrated elevated glomerular abundance of all three TGF-/3
isoforms in a variety of human glomerular diseases, suggesting
that TGF-p plays a pathogenetically relevant role [8]. TGF-/3
isoforms are secreted proteins which undergo extracellular acti-
vation [9]. Much evidence has been provided showing that
TGF-/31 can inhibit proliferation of various mesenchymal and
non-mesenchymal cell types and that it also regulates the expres-
sion and deposition of ECM proteins and stimulates expression of
integrin receptors [9, 10]. Multiple studies of MCs in culture have
confirmed the anti-mitogenic [11, 121 and ECM-promoting [12,
13] potential of TGF-/31. Also, in experimental glomerular dis-
ease, TGF-f31 has been reported to exhibit both beneficial anti-
mitogenic, anti-inflammatory effects [141 and harmful fibrogenic
action [15—171.
The anti-mitogenic action of TGF-131 in proliferative glomeru-
lar diseases is of particular interest. In cultured MCs, TGF-f31 has
been observed to stimulate cell proliferation at low concentrations
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(< 100 pg/mI), while it strongly inhibited MC proliferation at
higher concentrations (> 250 ng/ml) [11]. By using MCs as a
vector for gene delivery to the renal glomerulus, a recent study in
rats demonstrated that overexpression of active TGF-131 reduced
MC hypercellularity in anti-Thyl.1 nephritis [14].
It is presently unclear how the anti-mitogenic effects of TGF-/3
are mediated in MCs. Studies on various types of cultured cells,
including tumor cell lines, have provided evidence that TGF-13 can
induce cell cycle arrest by several mechanisms. Reports in epithe-
ha! cells have linked the growth-inhibitory action of TGF-13 to its
ability to block phosphorylation of the retinoblastoma gene
product (pRb) [18] and of the pRb-related protein p130 [19]. Such
effects of TGF-/3 appeared to be related to the induced expression
or activity of nuclear inhibitors of cyclin-dependent kinases
(cdks), such as pl5Th°4' [20, 211, p2i' [22], or p27°1 [23]. In
keratinocytes, TGF-/3 has been shown to directly interfere with
transcription of c-myc by repressing its promotor activity through
a TGF-j31 control element [24]. In the present study, we examined
growth-inhibitory effects of TGF-pl in cultured rat MCs in order
(1) to define more precisely the time phase during cell cycle
progression when MCs are sensitive to TGF-/31-related inhibition,
and (2) to identify regulatory steps of TGF-/31-induced cell cycle
arrest in MCs.
Methods
Cell culture
Glomeruli from kidneys of male Sprague-Dawley rats (200 g)
were isolated and glomerular outgrowth and subsequent subcul-
turing of MCs was performed as described previously [251. MCs
were kept in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% heat-inactivated (5 0°C, 30 mm) fetal calf
serum (FCS), 50 U/ml penicillin, 50 sg/ml streptomycin, 2 mrvi
glutamin, and 5 ig/m1 insulin in a 95% air/5% CO2 humidified
atmosphere at 37°C. MCs were used for experiments between
passages 5 and 20. Before addition of specific growth regulators,
MC quiescence was achieved by incubation for 72 hours in
DMEM supplemented with 0.5% heat-inactivated FCS, 50 U/ml
penicillin, 50 g/ml streptomycin, 2 mrvi glutamin, and 5 ig/ml
insulin. Unless otherwise indicated, peptide growth factors were
used in the following concentrations: PDGF-BB 25 ng/ml (Boehr-
inger, Mannheim, Germany); TGF-/31 5 ng/ml (Life Technolo-
gies, Eggenstein, Germany); endothelin-1 10 flM (Boehringer);
serotonin (5-HT) 1 m'vi (Sigma, Deisenhofen, Germany); bFGF
10 ng/ml (Boehringer); EGF 100 ng/ml (Boehringer).
Determination of 31—I-thymidine uptake
A total of 1.5 x iO MCs/well were seeded using 96-well plates
in medium supplemented with 10% FCS. After 24 hours, MCs
were growth-arrested by culture in medium supplemented with
0.5% FCS for 72 hours. Quiescent MCs were then exposed to
fresh medium containing 0.5% FCS with or without addition of
various growth factors and pulsed with 1 sCi/ml [3H-methyl]-
thymidine (specific activity 5 mCi/mmol; Amersham, Braun-
schweig, Germany). At indicated time points, MCs were washed
twice with PBS, lysed with dH2O and harvested onto filter paper
using an automated cell harvester (Bibby Dunn, Asbach, Germa-
ny). Incorporated counts were measured in a liquid scintillation
counter (Beckman, Munchen, Germany).
Determination of cell number
A total of 5 >< iO MCs/well were seeded onto 24-well plates
and grown to semiconfluence. Cells were then growth-arrested for
72 hours in medium supplemented with 0.5% FCS. Mitogenic
stimulation of MCs was performed as for 3H-thymidine uptake.
Cell numbers were determined at indicated time points. Mono-
layers were washed twice in PBS, MCs were trypsinized and
transferred into 10 ml of Isoton for counting in a coulter counter
(Coulter Electronics, Krefeld, Germany). For each value, three
wells were counted twice.
Flow cytometric analysis of DNA content
Four x iO MCs were seeded into 100 mm diameter dishes and
growth-arrested, as described above. Stimulation of MCs was
done for indicated times with indicated stimuli. Cells were washed
twice with PBS, harvested by tiypsinization, washed twice with
PBS and fixed in 70% ethanol in PBS for 30 minutes on ice. After
two washes with PBS, MCs were incubated with RNAse A (1
mg/mi) for 30 minutes at 37°C, washed twice with PBS, resus-
pended in 200 ml PBS and stained with 100 mg/mi propidium
iodide (Sigma). 5 X iO cells of each sample were analyzed with
a FACscan flow cytometer and the Lysis II software (Becton
Dickinson, Heidelberg, Germany).
Protein extraction and Western blot analysis
MCs were grown in 10 cm dishes until subconfluency, growth-
arrested for 72 hours in medium containing 0.5% FCS and
harvested after stimulation with indicated stimuli at indicated
time points in 100 il RIPA solution (50 mst Tris-HCI, pH 7.2, 10
mM EDTA, pH 7.2, 0.1% SDS, 1% sodium deoxycholate, 1%
Triton X-100, 0.6 mvi PMSF, 100 U/mi Trasylol, 2 jtg/mI leupep-
tin, 100 IIM sodium orthovanadate). Protein concentration was
determined using a commercially available assay based on the
Bradford dye binding procedure (BioRad). Protein samples con-
taining 20 tg total protein were denatured by boiling for five
minutes and separated on a 10% denaturing SDS-PAGE gel. For
detection of pRb, a 7.5% denaturing SDS-PAGE gel was used.
After electrophoresis, the gels were electroblotted onto NC
membranes (BioRad) and the transfer was controlled by Pon-
ceau-S staining. Blots were incubated in PBS containing 0.1%
Tween-20 and 5% non-fat dry milk powder to block unspecific
binding, washed in PBS containing 0.1% Tween-20 and incubated
with primary antibodies. Applied primary antibodies were di-
rected against: cyclin E, 1:500; cdk 2, 1:500; cyclin Dl, 1:500; cdk
4, 1:500; pRb, 1:500; all purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Applied secondary antibodies were
peroxidase-conjugated goat anti-rabbit IgG, 1:10000 (Dianova).
For visualization, the ECL system (Amersham) was used accord-
ing to the manufacturer's protocol.
RNA extraction and Northern blot analysis
MCs were grown in 10 cm dishes until subconfluency and
growth-arrested for 72 hours in medium containing 0.5% FCS.
After stimulation with indicated stimuli for indicated times, cells
were washed twice in PBS and total RNA was extracted by the
method of Chomczynski and Sacchi [26]. Ethanol-precipitated
RNA was dissolved in 1 X MOPS buffer, 50% formamide, 17.5%
formaldehyde, heat-denatured at 65°C for five minutes and sep-
arated on a 1% agarose formaldehyde gel [25]. Size-fractionated
* * I *
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RNA was transferred onto Hybond nylon membrane (Amer-
sham). Northern blots were baked at 80°C for two hours, prehy-
bridized with 5 X Denhardts, 5 X SSC, 50% formamide, 50 m
Na3PO4, 0.1% SDS, 0.25 mg/mI salmon sperm DNA at 65°C for
four hours. The DNA hybridization probes were labeled with
[a-32P]dCTP using a random primer labeling kit (Boehringer).
Blots were hybridized in prehybridization solution containing 2 ><
106 cpm/ml of probe at 55°C for 16 hours. Next, blots were washed
twice for 15 minutes with 2 X SSC containing 0.1% SDS and then
30 minutes with 0.1 >< SSC containing 0.1% SDS. Blots were
exposed to Kodak XAR-2 films with intensifying screens at
—80°C.
Cyclin E-associated histone Hi kinase activity
Seven hours after mitogenic stimulation whole-cell protein
extracts of MCs were prepared by lysis in hepes-buffer (50 mivi
Hepes, pH 7.0, 150 mM NaC1, 0.1% NP-40, 0.2 mvt PMSF, 100 fLM
sodium orthovanadate, 10 mivi 3-glycerophosphate, 1 mrvi NaF,
0,33 TIU/ml aprotinin). After preclearing with 40 pi protein
A-agarose, protein extracts (500 .tg) were immunoprecipitated for
one hour at 4°C with an antibody specific for cyclin E (Santa Cruz
Biotechnology), which during G1 phase is associated with active
cdk 2. Cyclin E-associated kinase activity in the immunoprecipi-
tates was determined using histone Hi as substrate [27]. Immune
complexes were resuspended in 35 d kinase buffer containing
0.26 mg/mI histone Hi (Sigma), 1 jtM cold ATP, 0.5 mCi/ml
[y-32P]ATP (Amersham), 50 mivi Tris/HCI pH 7.4, 10 ms MgCI2,
and 1 mivi DiT. After incubation for 30 minutes at 30°C, reactions
were terminated by heating at 95°C for 10 minutes. Phosphory-
lated products were analyzed on a 10% SDS-polyacrylamide gel
and visualized by autoradiography. Exposure time was about one
hour. After scanning densitometry, results were correlated with
cdk 2 protein abundance in each immunoprecipitate, assessed by
Western blot analysis. By Western blot, cdc 2 protein was not
detectable in cyclin E immune complexes from MCs lysed seven
hours after mitogenic stimulation.
Statistical analysis
Statistical analysis was performed using Student's t-test for
unpaired samples.
Results
TGF-/31 inhibits mitogen-induced proliferation of MCs
Initial studies were performed to obtain information on mito-
genic and anti-mitogenic effects and dose-responses of TGF-f31
and other MC growth regulators. TGF-131 (5 ng/ml) significantly
inhibited mitogenesis induced by PDGF (25 ng/ml), EGF (100
ng/ml), serotonin (1 mM), endothelin-i (10 nM), or bFGF (10
ng/ml), as assessed by 3H-thymidine uptake (Fig. 1), These results
indicated that the growth-inhibitory effects of TGF-f31 involve
mechanisms independent from the type and trans-receptor signal-
ing modes of different mitogens. To study anti-mitogenic signaling
mechanisms of TGF-/3i, we focused on the antagonistic growth-
regulatory effects of PDGF and TGF-f31. Figure 2 depicts dose-
dependent effects of PDGF and TGF-f3i in rat MCs. The
mitogenic response of MCs to PDGF resulted in a 4.4-fold
increase of 3H-thymidine incorporation at a concentration of 100
ng/ml (Fig. 2A). At higher concentrations, the mitogenic MC
response decreased slightly. In subsequent experiments, PDGF
- + I- l1 !l- I1- 1I- I
PDGF EGF 5-HT ET-1 bFGF
Fig. 1. Inhibition of MC DNA synthesis by TGF-f31. Subconfiuent cultured
rat MCs were growth-arrested and stimulated with either PDGF (25
ng/ml), EGF (100 ng/ml), serotonin (5-HT, 1 mM), endothelin-1 (ET-1, 10
nM), or bFGF (10 ng/ml), with or without addition of TGF-/31 (5 ng/ml).
3H-thymidine uptake was determined 24 hours after stimulation. Values
given are means SD of five samples. Significances were calculated
comparing unstimulated or mitogen-stimulated MCs to parallel samples
incubated with added TGF-131. *p < 0.05.
was applied at 25 ng/ml concentrations which induced a 3.4-fold
increase in MC DNA replication. Incubation of MCs with increas-
ing concentrations of TGF-131 induced a biphasic dose response
(Fig. 2B). A maximum 2.1-fold increase of DNA synthesis was
caused by 0.05 ng/ml TGF-131. However, higher (> 0.5 ng/ml) or
lower (< 0.005 ng/ml) concentrations of TGF-pl did not increase
3H-thymidine uptake. TGF-j31 concentrations >0.5 ng/ml further
decreased DNA synthesis of quiescent MCs.
TGF-/3i did not only prevent PDGF-induced DNA synthesis
(Fig. 1), but also significantly decreased MC proliferation elicited
by PDGF (Fig. 3). Counts of MCs incubated with PDGF (25
ng/ml) and/or TGF-f3i (5 ng/mI) were determined on days 2, 3 and
4 after stimulation (Fig. 3). While PDGF led to a 1.7-fold increase
of MC counts on day 4, incubation of MCs with TGF-/31 alone
had no effect. Simultaneous incubation of MCs with PDGF and
TGF-pl significantly inhibited the proliferative response of MCs,
roughly correlating with the results of DNA synthesis (Figs. 1 and
3). Since the number of TGF-f31 -treated cells did not fall below
the 0.5% FCS control value, toxicity of TGF-f31 at a concentration
of 5 ng/ml did not seem to be involved in its observed anti-
mitogenic effect.
Inhibition of PDGF-induced mitogenesis by TGF-131 is dependent
on time of addition
The results shown in Figure 4 indicate that TGF-pl did not
interfere with very early mitogenic signaling effects induced by
PDGF. Growth-arrested MCs were incubated with PDGF (25
ng/ml). TGF-/31 (5 ng/ml) was then added to PDGF-stimulated
MCs at time-points 0 to 18 hours. TGF-f31 significantly inhibited
PDGF-induced DNA synthesis when added within the first six
hours. The addition of TGF-pl at eight or more hours after
PDGF stimulation was no longer able to suppress MC growth
promotion initiated by PDGF. This finding led to the following
experiments addressing the question, which mitogenic signaling
events are target of TGF-pl.
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Fig. 3. TGF-/31 decreases PDGF-induced MC replication. Quiescent MCs
were stimulated with PDGF (0, 25 ng/ml), TGF-/31 (LI, 5 ng/ml), or
PDGF (25 nglml) plus TGF-131 (5 ng/ml, S). Cell counts of MCs were
determined at days 2, 3 and 4 after stimulation. Data were corrected for
growth of unstimulated MCs and the index of cell number indicated as the
x-fold increase over baseline values of unstimulated MCs. Values given are
means SD of five samples. Significances were calculated comparing
PDGF to PDGF plus TGF-/31-treated MCs. *D < 0.05.
TGF-131 prevents ently into S phase of the cell cycle
Studies in tumor cell lines have linked TGF-/3-induced anti-
mitogenic actions to G1 phase arrest. Therefore, we employed
flow cytometric analysis of DNA content to clarify how TGF-131
affects cell cycle distribution of cultured MCs (Fig. 5). Quiescent
MCs were stimulated with PDGF (25 ng/ml) or PDGF (25 nglml)
plus TGF-pl (5 nglml). MCs were harvested at various time
points ranging from 0 to 34 hours and percentages of cells in
G0/G1, 5, or G2/M phases of cell cycle were determined. By serum
deprivation, an average of 82% of MCs were arrested in G01G1
phase, 6% in S phase and 12% in G2/M phase. After PDGF
stimulation, the percentage of cells in G0/G1 phase decreased to
50% at 20 hours. A maximum of 28% ofMCs could be detected
in S phase at 16 hours (Fig. 5A). Entry into S phase occurred 14
hours after PDGF stimulation and exit from S phase was detected
between 20 and 24 hours. Coincubation with TGF-pl, however,
almost completely prevented PDGF-driven transition of MCs
from G01G1 phase into S phase (Fig. SB). Failure to enter S, G2
and M phases in the TGF-J31 -treated MCs could be due to arrest
in G phase or failure to enter G1 phase. To address this question,
the effects of TGF-131 on markers of PDGF-induced cell cycle
entry were examined for which we used expression of (1) imme-
diate early genes and of (2) G phase cyclins and cyclin-dependent
kinases.
TGF-pl does not affect PDGF-induced immediate early gene
(lEG) expression in MCs
Upon incubation with PDGF, Northern blot analysis demon-
strated a rapid and transient increase of mRNA abundance of the
lEGs, c-fos, Egr-1, and c-jun (Fig. 6). TGF-/31 did not change
mRNA expression of either one of these PDGF-induced lEGs.
Thus, interference with mitogen-related lEG expression did not
appear to be a target of anti-mitogenic signaling initiated by
TGF-pl.
Protein expression of the G1 phase cyclins and cyclin-dependent
kinases
The protein abundance of the G1 phase cyclins Dl, E and
cyclin-dependent kinases (cdks) 2 and 4 was determined by
Western blot (Fig. 7). Quiescent MCs were stimulated with PDGF
(25 ng!ml) or PDGF (25 nglml) plus TGF-131 (5 ng/ml). Cyclin E
was expressed at rather high abundance in quiescent MCs and its
expression level was only marginally enhanced after stimulation
with PDGF. However, incubation with PDGF caused an increase
in protein expression of cyclin Dl, cdk 2 and cdk 4 between 8 and
10 hours. Coincubation with TGF-131 did not influence the protein
abundance of either one of these proteins: the expression level of
cyclin E was not suppressed below baseline and the PDGF-
induced expression of cyclin Dl, cdk 2 or cdk 4 was not measur-
ably altered by TGF-pl. The finding that TGF-f31 did not
influence PDGF-induced expression of the lEGs, c-fos, Egr-1,
c-jun and of cyclin Dl, cdk 2 or cdk 4 indicated that anti-mitogenic
actions of TGF-f31 occur after MCs have entered G1 phase and
before progressing to S phase. Next, we examined how TGF-/31
interferes with molecular mechanisms involved in orderly progres-
sion through G1 phase.
TGF-/31 inhibits phosphoiylation of retinoblastoma protein
We examined whether regulation of retinoblastoma protein
(pRb) phosphorylation contributed to TGF-/31-induced G1 phase
arrest. In its hypophosphorylated state, pRb is active, inhibiting
progression from G1 into S phase [18]. On Western blots, the
A
16
B
14
12
10
8
6
4
2
0 -,
0 50 100 150 200 0
PDGF, ng/mI
1.8
. 1.6
E
.E 1.4
a)0
1.2
a) 1.0C
0
0.01 0.1 1
TGF-r31, ng/mI
Fig. 2. Dose-dependent effects of PDGF and
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proportions of hypo- or hyperphosphorylated pRb are apparent
by mobility shift. While the hypophosphorylated (active) protein
species is detected at 105 kDa, the hyperphosphorylated (inactive)
protein species migrates more slowly on gel electrophoresis and
can be detected between 110 and 116 kDa [28, 29]. As shown in
Figure 8, both high serum (10% FCS) and PDGF markedly
induced pRb phosphorylation in quiescent MCs within eight
hours after stimulation. Coincubation of PDGF-stimulated MCs
with TGF-/31 clearly inhibited pRb phosphorylation compared to
cells treated with PDGF alone. Incubation with TGF-131 alone
had no significant effect on pRb phosphorylation. These findings
demonstrated that TGF-f31-induced G1 phase arrest in PDGF-
stimulated MCs correlates with its effect to maintain the negative
cell cycle regulator pRb in its active, hypophosphorylated state.
TGF-131 inhibits mitogen-induced cyclin E-associated histone HI
kinase activity in rat MCs
We examined the effect of TGF-pi on mitogen-induced cyclin
F-associated histone Hi kinase activity. Active cyclin E-cdk 2
complexes contribute to phosphorylate pRb and are required for
progression of cells from G1 into S phase. As depicted in Figure
9, both, 10% FCS and PDGF strongly induced cyclin E-associated
histone Hi kinase activity in quiescent MCs at seven hours after
stimulation compared to 0.5% FCS controls. Coincubation of
Fig. 5. Effects of PDGF and TGF-f31 on cell
cycle distribution in rat MCs. Growth-arrested
MCs were stimulated with (A) PDGF (25 ng/
ml) or (B) PDGF (25 ng/ml) plus TGF-131 (5
nglml). MCs were harvested at various
timepoints ranging from 0 to 34 hours. Cell
cycle distribution of MCs was analyzed by flow
cytometric analysis of DNA content after
staining with propidium iodide. For each time
point, 5 X io MCs were analyzed. Values are
depicted as percentages of cells being in GD/G1
(A), S (•), or G2/M (0) phases of cell cycle,
respectively. The shown data are from one
representative (out of three) experiment.
PDGF-stimulated MCs with TGF-131 clearly inhibited cyclin
E-associated histone Hi kinase activity compared to MCs treated
with PDGF alone. Incubation of unstimulated control cells with
TGF-/31 had no effect on cyclin E-associated histone Hi kinase
activity. Because cyclin E does not have any known partner during
G1 other than cdk 2, the kinase activity that is down-regulated by
TGF-13i during G1 corresponds largely, if not exclusively, to the
activated cyclin E-cdk 2 complex. The cyclin E-associated cdk 2
protein amounts were assessed by Western blot analysis and were
not significantly altered by TGF-/31, indicating that TGF-J31 did
not interfere with the assembly of cyclin E-cdk 2 complexes in rat
MCs (data not shown). Calculated ratios of the densitometric
values of bands of histone Hi phosphorylation (Fig. 9B) over cdk
2 protein expression by Western blot revealed an 3.4-fold increase
for 10% FCS and an 3.3-fold increase for PDGF over 0.5% FCS
controls. Addition of TGF-f3 together with PDGF reduced this
effect to a value of 1.1-fold over controls.
Discussion
In inflammatory glomerular disease, glomerular hypercellular-
ity due to MC proliferation has been associated with the devel-
opment of glomeruloscierosis and progressive loss of renal func-
tion. The concept has been advanced that ongoing MC replication
also activates the synthetic-secretory phenotype of MCs which
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Fig. 4. Inhibition of PDGF-induced DNA
synthesis by TGF-/31 is dependent on time of
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Fig. 6. PDGF-induced lEG mRNA expression in
MCs is not affected by TGF-/31. Quiescent MCs
were stimulated with PDGF (25 nglml) or
PDGF (25 nglml) plus TGF-j31 (5 nglml). After
one, two, four, and six hours, total RNA was
extracted and subjected to Northern blot
analysis using c-fos, Egr-1, and c-jun eDNA
probes. Equal RNA loads were confirmed by
hybridization with a glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) eDNA probe.
contributes to mesangial ECM expansion and may ultimately lead
to glomerular scarring [2—41. In several animal models, stimula-
tion of MC proliferation was found to be related to increased
deposition of ECM [1, 2] and interventions inhibiting prolifera-
tion lessened matrix expansion [3, 4]. In contrast to the large
amount of information available on mitogenic mechanisms in-
volved in the pathogenesis of glomerular immune injury, little is
known about counterbalancing antiproliferative actions which
allow resolution of hypercellular glomerulonephritis (GN). Re-
cent reports have suggested protective, anti-inflammatory and/or
anti-mitogenic effects in the inflamed glomerulus for various
regulators and mechanisms, including (1) the anti-inflammatory
lymphokines IL-4 and IL-b that are secreted by T helper subset
2 lymphocytes [301, (2) apoptotic cell clearing mechanisms con-
tributing to reduction of MC hypercellularity [31, 32], and (3)
TGF-13 by virtue of its anti-inflammatory and anti-mitogenic
actions [14]. While a recent study has demonstrated that glomer-
ular overexpression of active TGF-1 significantly reduced gb-
merular mitogenesis in anti-Thy 1.1 nephritis [14], TGF-13 has also
been implied to promote accumulation of ECM in glomerular
disease [15—17]. The diverse effects of TGF-j3 have been found to
be mediated by different receptor-mediated signaling pathways,
with the type I TGF-13 receptors being responsible for effects on
ECM production, and the type II TGF-f3 receptors mediating
growth inhibition [33]. Little information exists on post-receptor
signaling pathways leading to anti-mitogenic actions of TGF-/3 in
MCs. Recently, TGF-J3 has been suggested to be an endogenous
activator of the growth inhibitory pathway mediated by protein
kinase C [34]. In the present study, we investigated nuclear
mechanisms involved in anti-mitogenic signaling by TGF-13 in
MCs.
Our results confirm that TGF-j31 modulates MC growth in a
biphasic manner with low concentrations inducing [11] and higher
concentrations inhibiting MC proliferation [11, 12]. The mecha-
nism of how TGF-131 increases MC proliferation at low concen-
trations around 0.05 ng/ml is presently unclear and remains the
subject of further investigation. At 5 ng/ml concentrations,
TGF-131 markedly inhibited proliferation of MCs stimulated with
various mitogens, including PDGF, EGF, serotonin, endothelin-1,
and bFGF. These results indicate that the growth-inhibitory
potential of TGF-f31 acts in a manner that is independent of the
type of mitogen receptor-mediated signaling pathway. Results
generated in other cell types have linked TGF-J3-induced anti-
mitogenic actions to 1 phase arrest [35]. We found that the
potential of TGF-131 to inhibit PDGF-induced mitogenesis was
dependent on the time of addition of TGF-31. It was limited to a
time period of up to eight hours after mitogenic stimulation.
Moreover, flow cytometric analysis of DNA content revealed that
TGF-131 inhibited progression of PDGF-stimulated MCs from
GO/G1 phase into S phase. Failure to enter S, 02 and M phases in
TGF-f3 1-treated MCs could be due to arrest in 01 phase or failure
to enter G1 phase. To further analyze this question, we studied
effects of TGF-/31 on markers of PDGF-induced cell cycle entry:
(1) induced expression of immediate early genes and (2) abun-
dance of G1 phase cyclins and cyclin-dependent kinases. TGF-/31
neither affected the mRNA induction of c-fos, c-jun or Egr-1 nor
the induction of the G1 phase proteins cdk 2, cdk 4 or cyclin Dl,
indicating that MCs had, indeed, entered G1 phase. We did not
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observe a marked PDGF-induced increase of cyclin E protein
expression. This could be explained by the high constitutive
abundance of cyclin E even in quiescent cultured MCs.
To address the question of how TGF-pl interferes with molec-
ular mechanisms involved in the progression through the G1
phase, we examined the phosphorylation of the negative cell cycle
regulator protein, pRb, in MCs. In its hypophosphorylated state,
the tumor supppressor pRb is active, thus inhibiting progression
from G1 phase into S-phase [18]. During progression of cells from
G1 phase into S phase, pRb is phosphorylated by active cyclin
D-cdk 4/6 and cyclin E-cdk 2 complexes [18]. We observed that
the PDGF-induced pRb phosphorylation in MCs was inhibited by
pRb phos
pRb
Fig. 7. TGF-P1 does not influence PDGF-induced protein expression of the Gi phase cyclins and cyclin-dependent kinases. Quiescent MCs were stimulated
with PDGF (25 ng/ml) or PDGF (25 ng/ml) plus TGF-f31 (5 ng/ml). MCs were harvested and protein was extracted I to 14 hours after stimulation.
Twenty jxg protein per lane was size-fractionated by SDS-PAGE and protein expression of cyclins Dl and E, as well as of cdks 2 and 4 was determined
by Western blot.
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Fig. 8. TGF-131 inhibits phosphotylation of retinoblastoma protein (pRb) phospho,ylation. Quiescent MCs were stimulated with 10% FCS (FCS 10%),
PDGF (25 ng/ml), or PDGF (25 nglml) plus TGF-pl (5 ng/ml). FCS 0.5% was used for control cells. Eight hours after stimulation, MCs were harvested
and protein was extracted. Twenty micrograms of protein per lane were size-fractionated by SDS-PAGE and protein expression of pRb was determined
by Western blot. The proportion of hypo- or hyperphosphorylated pRb is apparent by mobility shift: pRb denotes the hypophosphorylated (active)
species; pRb0 denotes the hyperphosphorylated (inactive) species.
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TGF-J31. The potential of TGF-f31 to inhibit pRb phosphorylation
has also been found in other cell types including renal proximal
tubule cells from the rabbit [29j. Preisig and Franch have consid-
ered this effect to contribute to TGF-j3-induced cell cycle-depen-
dent hypertrophy of renal epithelial cells [361.
Several molecular mechanisms have been proposed to explain
the ability of TGF-131 to prevent pRb phosphorylation. While
inhibition of pRb phosphorylation by TGF-f3 appears to be a
major cause of TGF--induced growth arrest in a variety of cell
types, there may be cell-specific preferences as to the molecular
mechanisms involved. For example, TGF-/31 reduced cdk 4 pro-
tein abundance in responsive epithelial cell lines [37]. In mitogen-
stimulated MCs, we did not observe a significant influence of
TGF-f31 on cdk 4 protein expression. Mink lung epithelial cells
treated with TGF-f3 failed to stably assemble cyclin E-cdk 2
complexes, which in turn caused decreased cdk 2 activity [27].
These effects of TGF-p were correlated with inhibition of pRb
phosphorylation [27]. In MCs, the cyclin F-associated cdk 2
protein amounts were not significantly altered by TGF-f31, indi-
cating that TGF-/31 did not interfere with the assembly of cyclin
E-cdk 2 complexes. However, we demonstrate that TGF-31
significantly inhibits PDGF-induced cyclin E- associated kinase
activity. Cyclin E does not have any known partner during G1
phase other than cdk 2. Therefore, the kinase activity that is
down-regulated by TGF-pl during G1 phase corresponds largely,
if not exclusively, to the activated cyclin E-cdk 2 complex. The
inhibition of cyclin E-cdk 2 kinase activity by TGF-pi may
represent an important mechanism leading to G1-arrest in MCs.
Recently, several nuclear inhibitors of cyclin-dependent kinases
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Fig. 9. TGF-f31 inhibits mitogen-induced cyclin
E-associated histone Hi kinase activity in rat
MCs. Quiescent MCs were stimulated with 10%
FCS, PDGF (25 ng/ml), or PDGF (25 ng/ml)
plus TGF-131 (5 ng/ml). FCS 0.5% was used for
control cells. After seven hours incubation,
whole-cell extracts were prepared and
immunoprecipitated with an anti-cyclin E
antibody. A. Cyclin E-associated kinase activity
in the immunoprecipitates was determined by
phosphorylation of histone Hi. B.
Densitometric analysis.
have been identified in non-glomerular cell types. Their expres-
sion or activity can be induced by TGF-J3. These cdk inhibitors
include p15'"41' [20, 21], p21C' [22] and p27" [23]. While
p15INK4b is an inhibitor of cdks 4 or 6, p2lC' and p27" were
shown to inhibit cdk 2 activities, as well. In preliminary experi-
ments, we have very recently observed that TGF-j31 increases
mRNA expression of p1 in resting rat MCs (Schoecklmann
and Sterzel, unpublished results). It is presently unclear whether
the anti-mitogenic effects of TGF-f31 on MCs involve the induc-
tion of this or other cdk inhibitors, such as p2l or p27. Recent
findings by Terada et al [38] and Shankland et al [39] have shown
that some of these nuclear proteins may well be relevant for the
regulation of cell cycle progression and proliferation of MCs in
culture and in vivo. Further studies are required to fully under-
stand the precise function of TGF-f3 and these regulators during
glomerular inflammation as well as their potential for diagnostic
and therapeutic approaches in mesangioproliferative diseases of
the kidney.
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